• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Pancreatic Cancer - Articles and news items

pancreatic cancer

Onivyde receives positive CHMP opinion for pancreatic cancer treatment

Industry news / 25 July 2016 / Niamh Louise Marriott, Digital Content Producer

The positive opinion is based on a pivotal Phase 3 study showing that Onivyde combined with chemotherapy significantly increased overall survival in patients with metastatic pancreatic cancer…

enzalutamide

Phase III enzalutamide trial initiated in mHSPC

Industry news / 29 March 2016 / Victoria White

The ARCHES trial will evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in mHSPC patients…

abiraterone

NICE recommends abiraterone for some prostate cancer patients

Industry news / 21 March 2016 / Victoria White

Professor Paul Workman of The Institute of Cancer Research, which discovered abiraterone, said the recommendation was “a big victory for men”…

PEGPH20

First patient dosed in Halozyme’s PEGPH20 pancreatic cancer trial

Industry news / 17 March 2016 / Victoria White

The trial will study PEGPH20 in combination with nab-paclitaxel and gemcitabine in patients with tumours that accumulate high levels of hyaluronan…

Abiraterone-acetate-plus-prednisone

Abiraterone acetate plus prednisone shows survival benefit in early mCRPC

Industry news / 14 March 2016 / Victoria White

In a study, abiraterone acetate plus prednisone provided an 11.8 months overall survival benefit compared to an active control of placebo plus prednisone…

Abraxane

Celgene’s Imnovid and Abraxane recommended for use in Ireland

Industry news / 29 February 2016 / Victoria White

Celgene has announced that that of the Health Service Executive (HSE) of Ireland has recommended two cancer treatments: Imnovid and Abraxane…

ruxolitinib

Incyte discontinues JANUS 1 study of ruxolitinib plus capecitabine

Industry news / 11 February 2016 / Victoria White

Incyte has explained that its decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation.

rp101

RedHill Biopharma and IZI enter RP101 collaboration

Industry news / 8 February 2016 / Victoria White

The research collaboration will test RP101 in preclinical oncology models in combination with standard-of-care chemotherapies to support existing Phase I and Phase II clinical data…

lynparza

FDA grants Breakthrough Therapy designation to Lynparza in mCRPC

Industry news / 28 January 2016 / Victoria White

This Lynparza BTD is for the treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer…

enzalutamide

STRIVE results for enzalutamide in CRPC published

Industry news / 27 January 2016 / Victoria White

The study achieved its primary endpoint demonstrating a statistically significant increase in PFS for enzalutamide compared with bicalutamide…

pancreatic cancer

New analyses of second-line treatment following AG in pancreatic cancer

Industry news / 25 January 2016 / Victoria White

Celgene has announced results from multiple analyses evaluating second-line treatments following Abraxane and gemcitabine (AG) in metastatic pancreatic cancer patients.

enzalutamide

Study results for enzalutamide vs. bicalutamide in prostate cancer published

Industry news / 14 January 2016 /

The TERRAIN study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival for enzalutamide compared to bicalutamide…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +